Securities code: Shanghai Raas Blood Products Co.Ltd(002252) securities abbreviation: Shanghai Raas Blood Products Co.Ltd(002252) Announcement No.: 2022037 Shanghai Raas Blood Products Co.Ltd(002252)
Suggestive announcement on the passive reduction of more than 1% of the company’s shares and 5% of the change in equity by the shareholder Kerui Tiancheng Investment Holding Co., Ltd. and its persons acting in concert
The shareholder Kerui Tiancheng Investment Holding Co., Ltd. guarantees that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The company and all members of the board of directors guarantee that the contents of the announcement are consistent with the information provided by the shareholder Kerui Tiancheng Investment Holding Co., Ltd.
Shanghai Raas Blood Products Co.Ltd(002252) (” Shanghai Raas Blood Products Co.Ltd(002252) ” or “the company”) received the letter on assisting in disclosing the passive reduction of Shanghai Raas Blood Products Co.Ltd(002252) shares held by Kerui Tiancheng Investment Holding Co., Ltd. and persons acting in concert issued by the shareholder Kerui Tiancheng Investment Holding Co., Ltd. (“Kerui Tiancheng”). From May 16, 2022 to May 20, 2022, Kerui Tiancheng and its concerted actor Ningbo Kerui Jinding investment partnership (limited partnership) (“Kerui Jinding”) passively reduced 76529082 shares of the company, accounting for 1.14% of the total share capital of the company; At the same time, the company received the short form equity change report issued by Kerui Tiancheng and its concerted actors Kerui Group Co., Ltd. (“Kerui group”) and Kerui Jinding. Since August 26, 2021, Kerui Tiancheng and its concerted actors have passively reduced 395108706 shares of the company, accounting for 5.86% of the total share capital of the company, and the reduced shares exceed 5% of the total share capital of the company.
In accordance with the relevant provisions of the securities law, the measures for the administration of the acquisition of listed companies, the standards for the content and format of information disclosure by companies that publicly issue securities No. 15 – Report on changes in equity, several provisions on the reduction of shares held by shareholders, directors, supervisors and senior managers of listed companies, and the detailed rules for the implementation of the reduction of shares held by shareholders, directors, supervisors and senior managers of Listed Companies in Shenzhen Stock Exchange, the specific situation is hereby announced as follows:
1、 Passive reduction of shares of the company
Shanghai Raas Blood Products Co.Ltd(002252) disclosed the pre disclosure announcement on the passive reduction of shares held by the shareholder Kerui Tiancheng on April 20, 2022 (Announcement No.: 2022017), First Capital Securities Co.Ltd(002797) (” First Capital Securities Co.Ltd(002797) securities”)
Within 6 months after 15 trading days from the date of publication of the pre disclosure announcement, the total holdings of Shanghai Raas Blood Products Co.Ltd(002252) shares will not exceed 2758 shares (accounting for Shenzhen Guohua Network Security Technology Co.Ltd(000004) % of Shanghai Raas Blood Products Co.Ltd(002252) total share capital) through centralized bidding trading. During the period from May 16, 2022 to May 20, 2022, First Capital Securities Co.Ltd(002797) securities sold a total of 1082 Shanghai Laishi shares through centralized bidding trading. Therefore, Kerui Tiancheng passively reduced 1082 Shanghai Raas Blood Products Co.Ltd(002252) shares (accounting for China Vanke Co.Ltd(000002) % of the total share capital of Shanghai Raas Blood Products Co.Ltd(002252) shares).
The Shanghai Raas Blood Products Co.Ltd(002252) 71528000 shares pledged by Kerui Tiancheng to Yingda Securities Co., Ltd. (“Yingda securities”) were enforced by the court for overdue repayment. The above 71528000 Shanghai Raas Blood Products Co.Ltd(002252) shares have completed the judicial transfer procedures in China Securities Depository and Clearing Co., Ltd. (“zhongdeng company”) on May 20, 2022 to offset the corresponding debts. Therefore, Kerui Tiancheng passively reduced 71528000 shares of Shanghai Raas Blood Products Co.Ltd(002252) shares (accounting for 1.06% of Shanghai Raas Blood Products Co.Ltd(002252) total share capital).
The 5000000 Shanghai Raas Blood Products Co.Ltd(002252) shares pledged to China Construction Investment Trust Co., Ltd. (“China Construction Investment Trust”) by Kerui Jinding, the concerted actor of Kerui Tiancheng, who provided guarantee for the third party, were enforced by the court due to the overdue repayment of the guaranteed party. The above 5000000 Shanghai Raas Blood Products Co.Ltd(002252) shares have completed the judicial transfer procedures in zhongdeng company on May 19, 2022 to offset the corresponding debts. Therefore, Kerui Jinding passively reduced its shareholding of Shanghai Raas Blood Products Co.Ltd(002252) shares by 5000000 shares (accounting for 0.07% of the total share capital of Shanghai Laishi). 1. Basic information
Information disclosure obligor: Kerui Tiancheng Investment Holding Co., Ltd
Address: floor 1, building 28, No. 6055, Jinhai highway, Fengxian District, Shanghai
Changes in equity from May 16, 2022 to May 20, 2022
Stock abbreviation Shanghai Raas Blood Products Co.Ltd(002252) stock code Shanghai Raas Blood Products Co.Ltd(002252)
Change type (increase □ decrease √ concerted action person yes √ no □
(multiple choice)
Whether it is the largest shareholder or actual controller yes □ no √
2. Changes in equity this time
Share types (A shares, B shares, etc.) number of shares reduced (10000 shares) reduction proportion (%)
A shares 0.1082 China Vanke Co.Ltd(000002) %
A shares 71528000 1.06%
A shares 50000000.07%
Total 76529082 1.14%
Centralized trading through stock exchange □
The way of equity change (multiple choices) is through the block trading of the stock exchange □
Others √ (please specify) execution of court decisions, etc
Self owned funds □ bank loans □
The capital source of this share increase (borrowing from other financial institutions □ shareholder investment □
(optional) others √ not applicable
Not involving the source of funds □
3. Shares of listed companies owned by investors and persons acting in concert before and after the change
Shares held before this change shares held after this change
Shareholders (February 20, 2025)
Proportion of said shares (10000 shares) to total share capital
Total shares held: 708753668 10.51% 6372245869.45% keruitian, of which: shares with unlimited sales conditions: 708753668 10.51% 6372245869.45% Cheng
Shares with limited sales conditions 0
Total shares held 228000000.34% 178000000.26%
Coregin, including: 228000000.34% 178000000.26% Ding shares with unlimited sales conditions
Shares with limited sales conditions 0
Keruitian holds a total of 731562302 shares, 10.85% 655033220 shares and 9.72% Chenghe
Among them: 731562302 shares with unlimited sales conditions 10.85% 655033220 9.72%
Actor
Kerui Gold Limited shares
Ding, Ke 0
Rui group 4 Performance of commitments, plans, etc
Whether this change has been performed yes □ no √
A promise, intention, plan
1. The reduction of Kerui Tiancheng and its concerted actors is due to the creditor’s application to the court to enforce the change. Whether there is any passive reduction caused by violation of the certificate, Kerui Tiancheng and its concerted actors have not been informed of the above-mentioned partial securities law, the passive reduction plan for acquisition and management of listed companies in advance, the above-mentioned partial passive reduction has not been pre disclosed, and the above-mentioned passive reduction has not produced any measures and other laws, administrative regulations What benefits; 2. Kerui Tiancheng and its persons acting in concert have been actively communicating and coordinating with creditors, and take relevant measures such as debt extension, fund-raising, margin call or collateral to prevent the risk of closing positions according to the business rules and other requirements of creditors; At the same time, it actively won the support of local government departments, and established a debt Committee in the third quarter of 2020 to seek strategic investors to jointly resolve the debt crisis.
5. Shares with restricted voting rights
According to Article 63 of the Securities Law
Yes □ no √
Voting shares 6 Further explanation on the increase of shares held by more than 30% shareholders (not applicable) 7 Documents for future reference 1. Details of shareholding changes of China Securities Depository and Clearing Co., Ltd. √ 2. Relevant written commitment documents □ 3. Written opinions of lawyers □ 4. Other documents required by Shenzhen Stock Exchange √
2、 Basic information of this equity change
According to the Shanghai Raas Blood Products Co.Ltd(002252) simplified equity change report issued by Kerui Tiancheng and its concerted actors Kerui group and Kerui Jinding on May 23, 2022, Kerui Tiancheng and its concerted actors passively reduced their holdings of Shanghai Raas Blood Products Co.Ltd(002252) shares from August 26, 2021 to May 20, 2022 due to the default disposal of stock pledge financing, totaling 395108706 shares, accounting for 5.86% of the total share capital of Shanghai Raas Blood Products Co.Ltd(002252) in total, The reduction of shares exceeds 5% of Shanghai Raas Blood Products Co.Ltd(002252) total share capital.
1. Shareholding of information disclosure obligor
Before this equity change (August 25, 2021), Kerui Tiancheng, the information disclosure obligor, and its persons acting in concert held 1050141926 Shanghai Raas Blood Products Co.Ltd(002252) shares, accounting for 15.58% of Shanghai Raas Blood Products Co.Ltd(002252) total share capital. (see Shanghai Raas Blood Products Co.Ltd(002252) simplified equity change report issued by Kerui Tiancheng and its concerted actors on August 27, 2021 for details). After this equity change (May 20, 2022), Kerui Tiancheng, the information disclosure obligor, and its persons acting in concert held 655033220 Shanghai Raas Blood Products Co.Ltd(002252) shares, accounting for 9.72% of Shanghai Raas Blood Products Co.Ltd(002252) total share capital.
Before and after the equity change, the information disclosure obligor Kerui Tiancheng and its persons acting in concert held the shares of the listed company as follows:
Before and after equity change
Name of shareholder (August 25, 2021) (May 20, 2022)
Number of shares (shares) shareholding ratio number of shares (shares) shareholding ratio
Kerui Tiancheng 95016697814.10% 6372245869.45%
Kerui Jinding 910363141.35% 178000000.2
